Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Blocking TGFß via Inhibition of the avß6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease. International journal of rheumatology Katsumoto, T. R., Violette, S. M., Sheppard, D. 2011; 2011: 208219

Abstract

Interstitial lung disease (ILD) is a commonly encountered complication of systemic sclerosis (SSc) and accounts for a significant proportion of SSc-associated morbidity and mortality. Its pathogenesis remains poorly understood, and therapies that treat SSc ILD are suboptimal, at best. SSc ILD pathogenesis may share some common mechanisms with other fibrotic lung diseases, in which dysregulation of lung epithelium can contribute to pathologic fibrosis via recruitment or in situ generation and activation of fibroblasts. TGFß, a master regulator of fibrosis, is tightly regulated in the lung by the integrin avß6, which is expressed at low levels on healthy alveolar epithelial cells but is highly induced in the setting of lung injury or fibrosis. Here we discuss the biology of avß6 and present this integrin as a potentially attractive target for inhibition in the setting of SSc ILD.

View details for DOI 10.1155/2011/208219

View details for PubMedID 22013449

View details for PubMedCentralID PMC3195527